Quartz·2 min read·medium

Eli Lilly is allowing more patients early access to its experimental weight loss drug

Cris Tolomia
AI Summary

Eli Lilly is expanding early access to its experimental weight loss medication for patients who do not qualify for clinical trials. The company will now review individual requests submitted by doctors.

The drugmaker said it will review requests from doctors for patients who cannot enroll in a clinical trial

Continue reading on Headlinne

Create a free account to read the full article.

Read full article →
businesshealth

Get the full story

Sign up for Headlinne to unlock AI insights, political bias analysis, and your personalized news feed.

Create free account

Already have an account? Sign in